Naurex Inc., a clinical-stage company focused on psychiatry and neurology, raised $38 million in Series B financing led by new investor Baxter Ventures. New investor Savitr Capital also participated in the financing, along with existing investors Adams Street Partners, Latterell Venture Partners, Genesys Capital, PathoCapital, Druid Bioventures, and Northwestern University, the company announced. Corporate investors Lundbeck, Takeda Ventures and Shire also contributed to the round. Naurex is based in Evanston, Illinois.
You are browsing the archive for Latterell Venture Partners - peHUB.
OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has promoted Jakob Dupont, formerly vice president, clinical research to senior vice president and chief medical officer. Privately-held, OncoMed’s investors include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay [...]
Transcend Medical Inc., a Menlo Park, Calif.-based ophthalmic device company, has closed a second tranche of its Series B round, bringing the total to an eye-popping $51 million. Investors include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. The company says it will use the funds to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. The company is focused on minimally invasive glaucoma therapies.
Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability.
Pathway Medical Technologies, a developer of endovascular treatments for peripheral arterial disease received a $1.5 million investment from Washington Research Foundation, independent, nonprofit foundation, as part of the company’s Series D financing. The round totals $42.5 million with investments from Forbion Capital Partners, Giza Venture Capital, HLM Venture Partners, Latterell Venture Partners, and Oxford Bioscience [...]